3 days Ago By ABMN Staff
Schroder Investment Management Group grew its stake in Bio-Rad Laboratories, Inc. ( NYSE:BIO – Free Report ) by 9.3% in the 4th quarter, according to its most recent filing with the SEC.
The firm owned 3,787 shares of the medical research company’s stock after buying an additional 322 shares during the quarter. Schroder Investment Management Group’s holdings in Bio-Rad Laboratories were worth $1,236,000 as of its most recent filing with the SEC. A number of other institutional investors and hedge funds have also made changes to their positions in the stock.
Strategic Financial Concepts LLC purchased a new position in Bio-Rad Laboratories in the fourth quarter worth approximately $3,561,000. Lecap Asset Management Ltd. acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $510,000.
Verition Fund Management LLC lifted its position in shares of Bio-Rad Laboratories by 193.3% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after purchasing an additional 2,287 shares during the last quarter.
Diversified Trust Co acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter worth $958,000. Finally, DAVENPORT & Co LLC increased its holdings in Bio-Rad Laboratories by 48.8% in the fourth quarter.
DAVENPORT & Co LLC now owns 84,677 shares of the medical research company’s stock valued at $27,817,000 after buying an additional 27,780 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.
Bio-Rad Laboratories Stock Down 4.1 % Shares of NYSE BIO opened at $225.21 on Monday.
The stock has a market cap of $6.31 billion, a PE ratio of -3.46 and a beta of 1.
12. Bio-Rad Laboratories, Inc. has a 52-week low of $221.
18 and a 52-week high of $387.99. The business has a 50-day moving average price of $281.
98 and a 200 day moving average price of $319.24. The company has a quick ratio of 4.
85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.
Wall Street Analysts Forecast Growth A number of analysts have issued reports on the company. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th.
Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th.
Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company.
According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $395.20.
Read Our Latest Analysis on BIO Bio-Rad Laboratories Company Profile ( Free Report ) Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Articles Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter ..
